



September 10, 2013

Esperion Therapeutics to Present at Stifel Nicolaus 2013 Healthcare Conference

PLYMOUTH, Mich.--(BUSINESS WIRE)-- Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that **Roger S. Newton**, Ph.D., Esperion's executive chairman, chief scientific officer and company founder, will present at the Stifel Nicolaus 2013 Healthcare Conference in Boston. Dr. Newton's presentation will take place on Wednesday, September 11, at 3:50 p.m. ET at the Four Seasons Hotel.

To hear the live audio webcast and view the slides of the Esperion presentation, please visit <http://www.veracast.com/webcasts/stifel/healthcare2013/28113409462.cfm>. A replay of the webcast will be available on the company's website for 30 days following the live event.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. ETC-1002 is targeted for statin intolerant patients with elevated levels of LDL-C. Esperion has completed seven clinical studies to date, including four Phase 2a studies, and expects to initiate a robust Phase 2b clinical program in the fourth quarter of 2013. For more information, please visit www.esperion.com.

BrewLife
Denise Powell, 510-703-9491
dpowell@brewlife.com

Source: Esperion Therapeutics

News Provided by Acquire Media